These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 31568022)

  • 1. Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease.
    Heisel CJ; Riddering AL; Andrews CA; Kahana A
    Ophthalmic Plast Reconstr Surg; 2020; 36(1):17-20. PubMed ID: 31568022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid eye disease in Eastern Province of Saudi Arabia: clinical profile and correlation with vitamin D deficiency.
    Alali M; Alkulaib NS; Alkhars A; Albadri K; Al Hassan S; Elewa M; Aldairi W; Alsaqer SK; Al-Abdulqader RA; Alhammad F
    Orbit; 2024 Feb; 43(1):28-32. PubMed ID: 36855900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of MMP-9 in the active phase of Graves' disease with and without ophthalmopathy.
    Riguetto CM; Barbosa EB; Atihe CC; Reis F; Alves M; Zantut-Wittmann DE
    Am J Physiol Endocrinol Metab; 2024 Oct; 327(4):E577-E584. PubMed ID: 39259164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors of Thyroid Eye Disease.
    Lee MH; Chin YH; Ng CH; Nistala KRY; Ow ZGW; Sundar G; Yang SP; Khoo CM
    Endocr Pract; 2021 Mar; 27(3):245-253. PubMed ID: 33655885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 25-Hydroxyvitamin D serum level in Hashimoto's thyroiditis, but not Graves' disease is relatively deficient.
    Ke W; Sun T; Zhang Y; He L; Wu Q; Liu J; Zha B
    Endocr J; 2017 Jun; 64(6):581-587. PubMed ID: 28413173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.
    Vargason CW; Chelnis JG; Barahimi BI; Mawn LA
    Semin Ophthalmol; 2016; 31(4):409-14. PubMed ID: 27385363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors.
    Bartalena L; Gallo D; Tanda ML; Kahaly GJ
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S2-S8. PubMed ID: 38054980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review.
    Mohamed A; Tzoulis P; Kossler AL; Dosiou C
    J Clin Endocrinol Metab; 2023 Mar; 108(4):979-985. PubMed ID: 36251747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid eye disease with choroidal folds.
    Tran AQ; Zhang-Nunes SX; Cahill K; Alabiad CR; Shriver EM; Ho T; Weinberg DA; Couch SM; Schlachter DM; Nguyen J; Wester ST
    Orbit; 2021 Jun; 40(3):206-214. PubMed ID: 32326785
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel inflammatory biomarkers in thyroid eye disease.
    Ueland HO; Ueland GÅ; Løvås K; Breivk LE; Thrane AS; Meling Stokland AE; Rødahl E; Husebye ES
    Eur J Endocrinol; 2022 Aug; 187(2):293-300. PubMed ID: 35675127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Graves' disease in patients with thyroid eye disease].
    Sviridenko NY; Sheremeta MS; Belovalova IM; Melnichenko GA
    Vestn Oftalmol; 2021; 137(6):128-135. PubMed ID: 34965078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum 25-hydroxyvitamin D predict prognosis in radioiodine therapy of Graves' disease.
    Li X; Wang G; Lu Z; Chen M; Tan J; Fang X
    J Endocrinol Invest; 2015 Jul; 38(7):753-9. PubMed ID: 25736544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
    Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
    Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy.
    Meling Stokland AE; Austdal M; Nedrebø BG; Carlsen S; Hetland HB; Breivik L; Ueland HO; Watt T; Cramon PK; Løvås K; Husebye ES; Ueland GÅ
    J Clin Endocrinol Metab; 2024 Feb; 109(3):827-836. PubMed ID: 37747433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of Diabetic and Nondiabetic Patients With Thyroid Eye Disease in the United States: A Claims-Based Analysis.
    Patel VK; Padnick-Silver L; D'Souza S; Bhattacharya RK; Francis-Sedlak M; Holt RJ
    Endocr Pract; 2022 Feb; 28(2):159-164. PubMed ID: 34781042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The "Quiet TED"-A Special Subgroup of Thyroid Eye Disease.
    Iñiguez-Ariza NM; Sharma A; Garrity JA; Stan MN
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):551-555. PubMed ID: 33782324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Vitamin D Status is Associated with Increased Thyrotropin-Receptor Antibody Titer in Graves Disease.
    Zhang H; Liang L; Xie Z
    Endocr Pract; 2015 Mar; 21(3):258-63. PubMed ID: 25370319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and thyroid eye disease (TED): a systematic review.
    Malboosbaf R; Maghsoomi Z; Emami Z; Khamseh ME; Azizi F
    Endocrine; 2024 Jul; 85(1):11-17. PubMed ID: 38194219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.
    Poon SHL; Cheung JJ; Shih KC; Chan YK
    Rev Endocr Metab Disord; 2022 Jun; 23(3):541-567. PubMed ID: 35066781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.